歐洲人類生物檢體市場：分析與預測（2025-2035）

歐洲人類生物檢體市場規模預計將從 2025 年的 8.818 億美元成長到 2035 年的 19.466 億美元，在 2025-2035 年預測期內的複合年成長率為 8.24%。

人體組織、血液、體液和分子衍生物是用於科學和醫學研究的人體生物材料。它們保留了真實世界的疾病特徵，對於研究分子路徑、檢驗診斷方法和開發個人化治療方案至關重要。透過標準化的採集、處理和儲存，生物樣本能夠保持其完整性並將其與臨床數據關聯起來，從而促進嚴謹的轉化研究，並推動精準醫學的進步。

市場概覽

歐洲人類生物檢體市場在推動該地區的生物醫學研究、藥物研發和精準醫療方面發揮關鍵作用。組織、血液、體液及其衍生樣本是人類生物檢體的重要組成部分，對於闡明疾病機制、識別生物標記和開發個人化治療方案至關重要。歐洲擁有完善的醫療保健體系、廣泛的醫院網路和值得信賴的學術研究機構，為生物樣本的採集和利用提供了堅實的基礎，尤其是在腫瘤學、罕見疾病和轉化醫學研究領域。

對品質、可追溯性和倫理管治的高度重視是歐洲生物樣本環境的顯著特徵。眾多由各國政府和歐盟資助計劃支持的公共和人群生物樣本庫，確保了獲取註釋完善且具有臨床意義的樣本。精準醫療和多體學研究日益成長的需求，使得與遺傳、臨床和生活方式數據關聯的縱向生物樣本變得至關重要。數位化生物銀行平台能夠同時提升資料整合、知情同意追蹤和樣本管理效率。

歐洲擁有嚴格的監管和高度的科學信譽，但其市場結構也較為複雜。嚴格的資料隱私規則、國家生物銀行法規以及高昂的營運成本可能會限制其可及性和擴充性。然而，對生物銀行基礎設施的持續投資、跨國合作以及標準化工作，已使歐洲人類生物檢體市場在促進生命科學創新方面佔據了戰略優勢。

市場區隔:

細分 1：按地區

• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲國家

歐洲人類生物檢體市場趨勢、促進因素與挑戰

市場趨勢

• 對高品質、註釋完善且與臨床和分子數據相符的生物樣本的需求不斷成長。
• 在西歐和北歐擴大基於人群和疾病特異性的生物樣本庫。
• 縱向和多體學相容的生物樣本正日益受到關注，以支持精準醫療。
• 擴大數位生物樣本庫管理系統在可追溯性、同意追蹤和數據整合方面的應用。
• 加強學術生物樣本庫、醫院、合約研究組織和製藥公司之間的合作。

主要市場促進因素

• 腫瘤學、免疫學和罕見疾病研究領域發展迅速，需要人類來源的樣本。
• 歐洲對個人化和精準醫療方法的接受度越來越高。
• 歐洲主要市場增加醫藥和生技研發投入。
• 公共資金和歐盟層面的舉措，以促進轉化研究和生物銀行的建立。
• 監管機構對樣品品質、標準化和道德採購的重視提高了可靠性和利用率。

主要挑戰

• GDPR 和國家生物銀行庫法律規定的嚴格監管和道德要求。
• 歐洲各國在知情同意框架和樣本取得規則方面存在差異。
• 與檢體採集、儲存、品管和合規相關的營運成本很高。
• 罕見疾病和高度特異性生物檢體的有限供應。
• 生物樣本庫與臨床和基因組資料庫之間資料整合的挑戰。

產品與創新策略：本報告深入分析了人類生物檢體領域的最新技術進展，使各組織能夠推動創新並開發符合市場需求的尖端產品。

成長與行銷策略：透過全面的市場分析與關鍵成長機會的識別，我們為企業提供製定有針對性的行銷策略並有效擴大市場佔有率所需的知識。

競爭策略：該報告包含全面的競爭格局分析，以幫助企業了解競爭對手的優勢和劣勢，並制定有效的策略以獲得市場競爭優勢。

監管和合規策略：提供有關不斷變化的法規結構、核准流程和行業指南的最新資訊，以確保您的組織保持合規，並加速新的人類生物檢體進入市場。

投資和業務擴大策略：透過分析市場趨勢、資金籌措模式和合作機會，我們幫助企業做出明智的投資決策，並識別潛在的併購機會以促進業務成長。

目錄

執行摘要

第1章 歐洲人類生物檢體市場：產業展望

• 市場概覽
  • 市場概況及趨勢
• 市場趨勢
  • 影響分析
  • 增加產品發布和監管核准
  • 加強參與企業、政府機構和學術機構之間的合作
• 供應鏈概覽
• 監管狀態
  • 歐洲
• 市場動態
  • 促進因素、限制因素和機會：評估當前和未來的影響
  • 市場促進因素
  • 市場限制
  • 市場機遇

第2章 區域

• 區域概況
• 歐洲
  • 區域概覽
  • 市場成長促進因素
  • 成長抑制因素
  • 市場規模及預測
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 其他

第3章 競爭標竿分析與公司概況

• 關鍵發展分析（依公司分類），2020-2025 年
• 公司簡介
  • Logical Biological
  • Europa Biosite
  • Grifols, SA

第4章調查方法

This report can be delivered in 2 working days.

Introduction to Europe Human Biospecimen Market

The Europe human biospecimen market is projected to reach $1,946.6 million by 2035 from $881.8 million in 2025, growing at a CAGR of 8.24% during the forecast period 2025-2035. Human tissues, blood, biofluids, and molecular derivatives are examples of biological materials that are extracted from the human body for use in scientific and medical research. They are crucial for researching molecular pathways, verifying diagnostics, and creating tailored treatments because they preserve the features of real-world diseases. Biospecimens facilitate precise translational research and propel advances in precision medicine through standardized collection, processing, and storage that maintain integrity and connect clinical data.

Market Introduction

The Europe human biospecimen market plays a critical role in advancing biomedical research, drug discovery, and precision medicine across the region. Tissues, blood, biofluids, and derived samples are examples of human biospecimens that are crucial for comprehending disease mechanisms, confirming biomarkers, and creating tailored treatments. Europe offers a solid basis for the collection and use of biospecimens, especially in oncology, rare illnesses, and translational research, thanks to its robust healthcare systems, vast hospital networks, and reputable academic research institutes.

The focus on quality, traceability, and ethical governance is a defining feature of the biospecimen landscape in Europe. Access to well-annotated, clinically relevant samples is ensured by the region's many public and population-based biobanks, which are backed by national governments and EU-funded projects. The need for longitudinal biospecimens connected to genetic, clinical, and lifestyle data is being driven by the growing demand for precision medicine and multi-omics research. Digital biobanking platforms are simultaneously enhancing data integration, consent tracking, and sample management.

Europe has strict regulations and strong scientific credibility, but the market is also structurally complex. Accessibility and scalability may be restricted by stringent data privacy rules, national biobanking regulations, and significant operating expenses. Nonetheless, the European market for human biospecimens is positioned as a strategically significant facilitator of life sciences innovation due to ongoing investments in biobanking infrastructure, cross-border cooperation, and standardization activities.

Market Segmentation:

Segmentation 1: By Region

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

Europe Human Biospecimen Market Trends, Drivers and Challenges

Market Trends

• Rising demand for high-quality, well-annotated biospecimens aligned with clinical and molecular data.
• Expansion of population-based and disease-specific biobanks across Western and Northern Europe.
• Increased focus on longitudinal and multi-omics-ready biospecimens to support precision medicine.
• Greater use of digital biobank management systems for traceability, consent tracking, and data integration.
• Growing collaboration between academic biobanks, hospitals, CROs, and pharmaceutical companies.

Key Market Drivers

• Strong growth in oncology, immunology, and rare disease research requiring human-derived samples.
• Increasing adoption of personalized and precision medicine approaches in Europe.
• Rising pharmaceutical and biotech R&D spending across major European markets.
• Supportive public funding and EU-level initiatives promoting translational research and biobanking.
• Regulatory emphasis on sample quality, standardization, and ethical sourcing, increasing trust and utilization.

Major Challenges

• Stringent regulatory and ethical requirements under GDPR and national biobanking laws.
• Variability in consent frameworks and sample access rules across European countries.
• High operational costs related to sample collection, storage, quality control, and compliance.
• Limited availability of rare disease and highly specific biospecimens.
• Data integration challenges between biospecimen repositories and clinical or genomic databases.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in human biospecimens, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new human biospecimens.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Table of Contents

Executive Summary

Scope and Definition

1 Europe Human Biospecimen Market: Industry Outlook

• 1.1 Market Overview
  • 1.1.1 Market Overview and Market Trends
• 1.2 Market Trends
  • 1.2.1 Impact Analysis
  • 1.2.2 Increasing Product Launches and Regulatory Approvals
  • 1.2.3 Increasing Collaboration between Players, Government Bodies, and Academia
• 1.3 Supply Chain Overview
• 1.4 Regulatory Landscape
  • 1.4.1 Europe
    • 1.4.1.1 Germany
    • 1.4.1.2 U.K.
• 1.5 Market Dynamics
  • 1.5.1 Drivers, Restraints, and Opportunities: Current and Future Impact Assessment
  • 1.5.2 Market Drivers
    • 1.5.2.1 Rising Adoption of Annotated Human Biospecimens
    • 1.5.2.2 Expansion of Biobanks and National Population Genomics Programs
    • 1.5.2.3 Surge in Cell and Gene Therapies, CAR-T, and Advanced Modalities
  • 1.5.3 Market Restraints
    • 1.5.3.1 Pre-Analytical Variability and Poor Biospecimen Quality
    • 1.5.3.2 Logistical, Storage, and Operational Challenges across the Biospecimen Lifecycle
  • 1.5.4 Market Opportunities
    • 1.5.4.1 Commercialization of Disease-Specific Rare-Disease Cohorts

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 Market Sizing and Forecast
  • 2.2.5 U.K.
    • 2.2.5.1 Country Overview
    • 2.2.5.2 Market Sizing and Forecast
  • 2.2.6 Germany
    • 2.2.6.1 Country Overview
    • 2.2.6.2 Market Sizing and Forecast
  • 2.2.7 France
    • 2.2.7.1 Country Overview
    • 2.2.7.2 Market Sizing and Forecast
  • 2.2.8 Italy
    • 2.2.8.1 Country Overview
    • 2.2.8.2 Market Sizing and Forecast
  • 2.2.9 Spain
    • 2.2.9.1 Country Overview
    • 2.2.9.2 Market Sizing and Forecast
  • 2.2.10 Rest-of-the- Europe
    • 2.2.10.1 Country Overview
    • 2.2.10.2 Market Sizing and Forecast

3 Competitive Benchmarking and Company Profiles

• 3.1 Key Developments Analysis (by Company), 2020-2025
• 3.2 Company Profiles
  • 3.2.1 Logical Biological
    • 3.2.1.1 Overview
  • 3.2.2 Europa Biosite
    • 3.2.2.1 Overview
  • 3.2.3 Grifols, S.A.
    • 3.2.3.1 Overview

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Inclusion and Exclusion
  • 4.1.4 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Human Biospecimen Market (by Scenario), $Million, 2024, 2028, and 2035
• Figure 2: Europe Human Biospecimen Market, 2024 and 2035
• Figure 3: Europe Human Biospecimen Market Snapshot
• Figure 4: Human Biospecimen Market, $Million, 2024 and 2035
• Figure 5: Supply Chain Flow
• Figure 6: Europe Human Biospecimen Market, $Million, 2024-2035
• Figure 7: U.K. Human Biospecimen Market, $Million, 2024-2035
• Figure 8: Germany Human Biospecimen Market, $Million, 2024-2035
• Figure 9: France Human Biospecimen Market, $Million, 2024-2035
• Figure 10: Italy Human Biospecimen Market, $Million, 2024-2035
• Figure 11: Spain Human Biospecimen Market, $Million, 2024-2035
• Figure 12: Rest-of-Europe Human Biospecimen Market, $Million, 2024-2035
• Figure 13: Inclusion and Exclusion Criteria for the Europe Human Biospecimen Market
• Figure 14: Data Triangulation
• Figure 15: Top-Down and Bottom-Up Approach
• Figure 16: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Key Market Trends
• Table 3: Product Launches and Regulatory Approvals in the Human Biospecimen Market
• Table 4: Collaborations in the Human Biospecimen Market
• Table 5: Human Biospecimen Market (by Region), $Million, 2024-2035
• Table 6: Key Strategies and Developments, 2020-2025